Breast Cancer Immunotherapy: A Journey from Cold to Hot
The field of breast cancer treatment has seen a remarkable evolution, particularly in the realm of immunotherapy. Dr. Sarah Poland, a leading expert in the field, delves into this transformative journey in her recent publication, 'Advances in Immunotherapy for Breast Cancer.'
A Shift in Perspective
Historically, breast cancer was often perceived as a 'cold' tumor, lacking the ability to trigger an immune response due to its low mutational burden and sparse tumor-infiltrating lymphocytes (TILs). However, Dr. Poland's research highlights a paradigm shift. She emphasizes the importance of studying triple-negative breast cancer (TNBC), which often exhibits higher PD-L1 expression and immune infiltration, challenging the traditional view.
Clinical Milestones
The article underscores several pivotal clinical trials that have solidified immunotherapy's place as a standard of care:
- Early-Stage TNBC: The KEYNOTE-522 trial demonstrated the efficacy of combining pembrolizumab (Keytruda) with chemotherapy as a neoadjuvant treatment for stage II to III TNBC. This trial was a game-changer, paving the way for new treatment protocols.
- Metastatic TNBC: In the KEYNOTE-355 trial, pembrolizumab showed significant benefits for patients with PD-L1-positive metastatic disease, offering new hope for those with advanced cancer.
Managing Toxicity and Rechallenge
Dr. Poland also addresses a critical aspect of immunotherapy: managing toxicity and rechallenging. She explains that while rechallenging with pembrolizumab after an immune-related adverse event (irAE) is possible, it demands a highly individualized approach, considering the severity and timing of the initial toxicity.
The Future of Immunotherapy
Looking ahead, the discussion extends beyond PD-1/PD-L1 inhibitors. Dr. Poland explores emerging technologies that hold the promise of revolutionizing treatment:
- Antibody-Drug Conjugates (ADCs): Novel combinations of ADCs with immunotherapy are being investigated, offering potential synergies.
- Emerging Modalities: Bispecific antibodies and vaccine trials utilizing tumor antigens are on the horizon, presenting exciting possibilities.
- Subtype Expansion: There is growing evidence supporting the effectiveness of immunotherapy in hormone receptor-positive and HER2-positive subtypes, expanding the scope of treatment beyond TNBC.
Addressing Educational Gaps
Dr. Poland underscores the importance of educational resources that bridge the gap between complex trial data and clinical practice. She emphasizes the need to address patient concerns regarding the newest therapies and trials, ensuring that patients and providers have access to accurate and understandable information.
About the Author
Dr. Sarah Poland is a renowned expert in the Department of Medicine, Section of Hematology/Oncology, at The University of Chicago. Her research contributes significantly to the advancement of breast cancer immunotherapy, offering valuable insights for both healthcare professionals and patients.
